The company’s head of oncology, Dave Fredrickson, said the approval of Truqap “reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need to test ...
In this video, Aruna Padmanabhan, MD, discusses therapy combinations for the treatment of PIK3CA-mutated metastatic breast cancer.
The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback